



Universiteit
Leiden
The Netherlands

Apolipoprotein L genes are novel mediators of inflammation in beta cells

Paz-Barba, M.; Garcia, A.M.; Winter, T.J.J. de; Graaf, N. de; Agen, M. van; Sar, E. van der; ... ; Carlotti, F.

Citation

Paz-Barba, M., Garcia, A. M., Winter, T. J. J. de, Graaf, N. de, Agen, M. van, Sar, E. van der, ... Carlotti, F. (2023). Apolipoprotein L genes are novel mediators of inflammation in beta cells. *Diabetologia*, 67, 124-136. doi:10.1007/s00125-023-06033-z

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3714429>

Note: To cite this publication please use the final published version (if applicable).



Apolipoprotein L genes are novel mediators of inflammation in beta cells

Miriam Paz-Barba¹ · Amadeo Muñoz Garcia¹ · Twan J. J. de Winter¹ · Natascha de Graaf¹ · Maarten van Agen¹ · Elisa van der Sar¹ · Ferdy Lambregtse¹ · Lizanne Daleman¹ · Arno van der Slik² · Arnaud Zaldumbide² · Eelco J. P. de Koning¹ · Françoise Carlotti¹

Received: 16 June 2023 / Accepted: 22 August 2023 / Published online: 4 November 2023
© The Author(s) 2023

Abstract

Aims/hypothesis Inflammation induces beta cell dysfunction and demise but underlying molecular mechanisms remain unclear. The apolipoprotein L (APOL) family of genes has been associated with innate immunity and apoptosis in non-pancreatic cell types, but also with metabolic syndrome and type 2 diabetes mellitus. Here, we hypothesised that *APOL* genes play a role in inflammation-induced beta cell damage.

Methods We used single-cell transcriptomics datasets of primary human pancreatic islet cells to study the expression of *APOL* genes upon specific stress conditions. Validation of the findings was carried out in EndoC- β H1 cells and primary human islets. Finally, we performed loss- and gain-of-function experiments to investigate the role of *APOL* genes in beta cells.

Results *APOL* genes are expressed in primary human beta cells and *APOLI*, 2 and 6 are strongly upregulated upon inflammation via the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway. *APOLI* overexpression increases endoplasmic reticulum stress while *APOLI* knockdown prevents cytokine-induced beta cell death and interferon-associated response. Furthermore, we found that *APOL* genes are upregulated in beta cells from donors with type 2 diabetes compared with donors without diabetes mellitus.

Conclusions/interpretation APOLs are novel regulators of islet inflammation and may contribute to beta cell damage during the development of diabetes.

Data availability scRNAseq data generated by our laboratory and used in this study are available in the Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/), accession number GSE218316.

Keywords Apolipoprotein L · Beta cells · Human islets · Inflammation

Abbreviations

APOL	Apolipoprotein L
ER stress	Endoplasmic reticulum stress
FGF2	Fibroblast growth factor 2
IRF	Interferon regulatory factor
JAK	Janus kinase
PI	Propidium iodide
qPCR	Quantitative PCR
STAT	Signal transducer and activator of transcription

Introduction

Inflammation is one of the most studied causes of beta cell failure. Specifically, exposure to proinflammatory cytokines has been shown to impair beta cell function and increase beta cell death [1–3]. Cytokine-induced beta cell damage is regulated via a broad spectrum of pathways. IL-1 β can induce inflammation and eventually cell death via NF- κ B activation and expression of proinflammatory genes (e.g. *iNOS* [also known as *NOS2*] and *CXCL10*) [4]. IFN γ activates the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, which leads to STAT translocation to the nucleus and upregulation of target inflammation genes (e.g. interferon regulatory factors [IRFs]) [5, 6]. In addition, the combination of IFN γ + IL-1 β can also trigger cell death via the endoplasmic reticulum (ER) stress pathway and the increase in the pro-apoptotic genes *ATF3*

✉ Françoise Carlotti
f.carlotti@lumc.nl

¹ Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands

² Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands

Research in context

What is already known about this subject?

- Inflammation is linked to beta cell failure and diabetes onset
- Apolipoprotein L (APOL)1 has been reported as a circulating biomarker for insulin resistance and the metabolic syndrome
- *APOL* genes belong to a gene family associated with inflammation-induced cell death, but no research has been performed in beta cells

What is the key question?

- Does the *APOL* gene family play a role in inflammation-induced beta cell damage?

What are the new findings?

- *APOL* genes are expressed in primary human beta cells upon inflammation
- The *APOL* gene family mediates cytokine-induced beta cell stress and death, and interferon-associated response
- *APOL* genes were found to be upregulated in beta cells from donors with type 2 diabetes mellitus

How might this impact on clinical practice in the foreseeable future?

- Targeting *APOL* may protect beta cells from the inflammation-related detrimental effects of diabetes

and *CHOP* [7, 8]. In a vicious cycle, the cytokine-induced expression of proinflammatory genes via the different pathways mentioned can also lead to the amplification of inflammatory signalling and contribute to cell death.

Targeting inflammation-related pathways has already shown promise for protecting beta cells in the context of both type 1 diabetes mellitus [9, 10] and type 2 diabetes mellitus [11–13]. For example, low-dose IL-2 treatment in children with recently diagnosed type 1 diabetes resulted in maintained C-peptide production over 1 year [9]. Interestingly, the combination therapy of liraglutide (a glucagon-like peptide 1 [GLP-1] analogue) and anti-IL-21 antibody resulted in enhanced C-peptide secretion over 54 weeks in adults with recent-onset type 1 diabetes [10]. In the field of type 2 diabetes, blockade of IL-1 β with IL-1 receptor antagonists reduced inflammation and improved and/or prevented diabetes in a rat model of type 2 diabetes [11], high-fat diet-fed mice [12] and in individuals with type 2 diabetes [13]. Therefore, the identification of novel targets involved in inflammation-related beta cell damage is relevant for the design of novel therapeutic treatments that could prevent or attenuate beta cell failure in both main types of diabetes.

Apolipoprotein L (*APOL*) genes belong to a conserved gene family involved in innate immunity. In humans, this gene family codes for six structurally similar proteins (*APOL*1–6). *APOL* gene expression is induced by innate

immunity-related pathways such as interferons [14–16], polyinosinic:polycytidylic acid [poly(I:C)] in endothelial cells and lipopolysaccharides in podocytes [17], among other cell types. The most well-studied *APOL* protein is *APOL*1, and it contains a pore-forming domain (PFD) that consists of a BCL2 homology domain 3 (BH3)-motif, a membrane-address domain (MAD) and a serum resistant-associated (SRA) domain [18, 19]. In addition, *APOL*1 has a signal peptide domain that enables its secretion extracellularly [20]. Functions associated with the *APOL* family include lipid transport [21, 22], mitochondria-regulated apoptosis [23, 24] and autophagy [25, 26]. In addition, *APOL*1 risk variants cause lysosomal cell death and cell membrane pore formation, as part of their cell defence mechanism against *Trypanosoma* infection [18, 19]. Evidence linking *APOL*s and diabetes is still very scarce. Croyal et al recently reported a positive association between basal serum *APOL*1 levels and the risk of developing type 2 diabetes [27]. This was in agreement with previous studies in which an association was found between *APOL*1 concentrations and plasma triglycerides [28] and/or the metabolic syndrome [29].

While the presence of *APOL* genes has been reported in the pancreas [30], its putative role in beta cell function and the onset or progression of diabetes remains unknown. Here, we have investigated the effect of *APOL* during inflammation-induced beta cell damage.

Methods

Human islets and cell lines Human islets were isolated from pancreases of cadaveric donors through the Eurotransplant multiorgan donation programme. Islets were used for research only if they could not be used for clinical purposes, and if research consent was present, according to Dutch National Laws. Human islets with a purity >80% were cultured in ultra-low attachment plates (Corning ref. 3471, USA) with CMRL 1066 (Corning, 99-663-CV, 5 mmol/l glucose), supplemented with 10% FCS, 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml gentamycin, 20 µg/ml ciprofloxacin, 10 mmol/l HEPES and 1.2 mg/ml nicotinamide. Donor characteristics are listed in electronic supplementary material (ESM) Table 1. Donors were considered to have type 2 diabetes if a history of diabetes was recorded, and/or the HbA_{1c} level was >48 mmol/mol (6.5%) and there was no indication of other types of diabetes mellitus. Donors were considered to have prediabetes if the HbA_{1c} level was between 39 mmol/mol (5.7%) and 46 mmol/mol (6.4%), according to the ADA guidelines [31].

The EndoC-βH1 cell line [32] was obtained from Univer-cell Biosolutions (Toulouse, France). Cells were seeded in ECM/fibronectin coated plates and cultured with low glucose DMEM (Invitrogen, USA) supplemented with 10 mmol/l nicotinamide, 5.5 g/ml transferrin, 6.7 ng/ml selenite, penicillin-streptomycin and 50 µmol/l β-mercaptoethanol.

HEK293T cells (ATCC, CRL-3216) were cultured in DMEM + 10% FCS. All cell lines are regularly checked for potential mycoplasma infection in our laboratory.

Induction of stress conditions Human islets were exposed for 24 h or 72 h to 1 ng/ml IL-1β (401-ML, R&D systems) + 50 ng/ml IFNγ (285-IF, R&D systems, USA) (cytokines). EndoC-βH1 cells were treated for 24 h or 72 h with 1 ng/ml IL-1β + IFNγ 50 ng/ml (cytokines), 1, 2 or 4 µmol/l baricitinib (a JAK–STAT inhibitor, HY-15315, MedChemExpress, USA) and 1, 2.5 or 5 µmol/l Bay 11-7082 (196871, Merck, Germany) or 50 µg/ml salicylate (S3007, Merck) (NF-κB inhibitors).

Single-cell RNA-sequencing We used our single-cell RNA-sequencing Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/) dataset generated from human pancreatic islets treated with beta cell stressors (GSE218316) and performed a differential gene expression analysis of human islet cells treated with IL-1β + IFNγ using a Wilcoxon rank-sum test. We considered genes to be significantly altered if they had an adjusted *p* value (based on Bonferroni correction) <0.05.

Transcriptomic analysis of type 2 diabetes datasets Four previously published SMART-seq (GEO GSE83139 [33], GSE81608 [34]) or SMART-seq2 (GEO GSE81547 [35], European Bioinformatics Institute E-MTAB-5061 [36])


scRNA-seq datasets of human pancreatic islets were selected for analysis. Differential gene expression in islets from donors without diabetes and with type 2 diabetes was statistically computed using an unpaired *t* test. See ESM Methods section for details.

Cell-death staining Cell death was assessed by using the ReadyProbes Cell Viability Imaging Kit (R37610, Thermo Fisher, USA). EndoC-βH1 cells were incubated with propidium iodide (PI) and Hoechst 33342 for 20 min and imaged with the ImageXpress confocal microscope (Molecular Devices, USA). Blinded quantification was performed with Fiji (2016, <https://imagej.net/software/fiji/downloads>) by using a nucleus-counting macro.

RT-qPCR RNA (250–500 ng) was obtained from human islets and EndoC-βH1 cells by cell lysis with RLT buffer with β-mercaptoethanol according to the manufacturer's instructions (micro RNeasy kit from Qiagen, Hilden, Germany). Isolated RNA was reverse-transcribed to DNA with M-MLV reverse transcriptase (Invitrogen), oligo(dT)s (Qiagen), dNTP (Promega, USA), DTT (Invitrogen) and RNase-OUT (ThermoFisher). Quantitative PCR (qPCR) was performed with IQ SYBR green mix (170–8887, Bio-Rad, Hercules, USA). *GAPDH* and *ACTB* were used as housekeeping genes. Amplification and detection were performed by using CFX systems (Bio-Rad) and fold changes were obtained by using the 2^{−ΔΔC_t} method. Primers are included in ESM Table 2.

Immunohistochemistry and fluorescence microscopy Coverslip-cultured EndoC-βH1 cells, isolated human islets or pancreatic tissue samples were fixed in 4% formaldehyde solution and embedded in 2% agar and paraffin. Samples were sectioned into 4 µm slides using the Leica microtome (RM2255, Leica, Germany). Slides were deparaffinised and rehydrated. Blocking was done with 5% normal donkey serum followed by primary and secondary antibody incubations. For nuclei staining, an extra step with 1% Triton X-100 was performed. Immunofluorescence was detected with a Leica microscope (Leica SP8). Antibodies used are listed in ESM Table 3.

Western blotting After treatment, approximately 3.000 islet equivalents or 350.000 EndoC-βH1 cells were washed with cold PBS and lysed in RIPA lysis and extraction buffer with 1/100 protease and phosphatase inhibitor (Thermo Fisher). Lysates were passed ten times with a 26-gauge needle and centrifuged to obtain the supernatant. Protein content was measured by BCA protein content kit (Thermo Fisher) and 10–20 µg protein was loaded in 12% mini-PROTEAN TGX gels (Bio-Rad) and transferred to 0.2 µmol/l PVDF membranes (Trans-blot turbo mini 0.2 µmol/l PVDF transfer packs, Bio-Rad). Membranes were blocked with 5% Milk in PBS-Tween for 1 h, incubated with primary antibody overnight at



◀ **Fig. 1** Cytokines increase *APOL* expression in human islets and beta cells. **(a)** Dotplot from scRNA-seq analysis shows the mean and percentage expression of *APOL* genes in beta cells exposed to different stressors for 24 h and 72 h (merged timepoints). Human islets **(b, e)** and EndoC- β H1 cells **(c, d, e)** were treated with IL-1 β + IFN γ (Cytokines) for 24 h and 72 h. **(b–e)** Gene and protein expression of *APOL1*, *APOL2* and *APOL6* were determined by qPCR **(b, c)**, western blot **(d)** and immunofluorescence staining **(e)**. *ACTB* and *GAPDH* were used to normalise mRNA expression and tubulin was used as loading control for western blots. **(e)** Fluorescence double staining of *APOL* proteins (green) and DAPI for nuclei (blue) was performed in EndoC- β H1 cells and human islets. Scale bar, 100 μ m. **(b, c)** Results are the means \pm SEM of 3–6 independent experiments; ** p <0.01, *** p <0.001, by paired **(b)** or unpaired **(c)** Student's t test

4°C, and after three washes with PBS-Tween, incubated for 1 h with secondary antibody at room temperature. Primary and secondary antibodies were diluted in the same buffer as the one used for blocking the membrane. Blots were incubated with Supersignal West Pico PLUS Chemiluminescent substrate (Thermo Fisher), visualised with Bio-Rad ChemiDoc Touch (Bio-Rad) and analysed with Image Lab (version 6.1, Bio-Rad). Antibodies used are listed in ESM Table 3.

Lentivirus-mediated overexpression and knockdown For overexpression, open reading frames (ORFs) of *APOL1* and *APOL2* in pDONR223 vector were picked from the MISSION TRC3 Human LentiORF Collection (Sigma-Aldrich), amplified by PCR using the following primers: *APOL1* forward (XhoI): TTCTCGAGATGGAGGGAGCTG; *APOL1* reverse (XbaI): AATCTAGAGGCTTGTGTCCACC; *APOL2* forward (XhoI): TTCTCGAGATGATCCAGAGAGC; *APOL2* reverse (XbaI): AATCTAGATGGTCTTGGCCTGGC; and subsequently subcloned into pLV-CMV-IRES-puro vector (XhoI/XbaI) for expression. All constructs were verified by sequencing.

The shRNA lentiviral constructs against *APOL1*, *APOL2* and *APOL6* were obtained from the MISSION shRNA library (clones TRCN118633, TRCN83107, TRCN151077, Sigma-Aldrich) and produced as described previously [37].

For transduction, EndoC- β H1 cells were infected with a multiplicity of infection (MOI) of 1 in DMEM/polybrene overnight. After, cells were washed in PBS and replaced with fresh DMEM for 48 h or 72 h, for overexpression or knockdown experiments, respectively.

siRNA-mediated knockdown EndoC- β H1 cells were transfected overnight with 30 nmol/l siRNA targeting human *STAT1* (ON-target SMARTpool human si*STAT1*, L-003543-00, Horizon Discovery, Cambridge, UK), or non-target control (ON-TARGETplus Non-targeting siRNAs, D-001810-01, Horizon Discovery). Transfection was performed with Dharmafect transfection reagent (Horizon Discovery) as described in the manufacturer's instructions. After 48 h, cytokines were added for 24 h.

Statistics Results are represented as mean \pm SEM. Comparisons were performed by two-tailed student t test and a p value <0.05 was considered significant.

Results

***APOL* genes are expressed in primary human beta cells and upregulated upon inflammation** We first set out to determine whether *APOL* genes are expressed in primary human pancreatic beta cells using our single-cell RNA-seq dataset from primary human islets exposed to diverse metabolic and inflammatory stressors in parallel: glucose (22 mmol/l) + palmitate (0.5 mmol/l), thapsigargin (0.1 μ mol/l), IL-1 β (1 ng/ml) + IFN γ (1000 U/ml), IFN α (2000 U/ml), fibroblast growth factor 2 (FGF2; 100 ng/ml) or hypoxia for 24 h and 72 h.

In the untreated condition, *APOL2* and *6* were the most highly expressed in beta cells (Fig. 1a). Upon IL-1 β + IFN γ treatment *APOL1*, *APOL2* and *APOL6* gene expression was significantly increased in beta cells, and *APOL2* and *APOL6* was increased in IFN α -treated cells. By contrast, no upregulation of *APOL* genes was found in beta cells exposed to glucose + palmitate, thapsigargin, hypoxia or FGF2 treatments (Fig. 1a and ESM Table 4).

Cytokine-induced expression of *APOL1*, *APOL2* and *APOL6* was validated by qPCR in human islets (Fig. 1b) and EndoC- β H1 cells (Fig. 1c) exposed to IL-1 β + IFN γ . In addition, we found a significant upregulation of *APOL1*, *APOL2* and *APOL6* protein levels upon inflammation in EndoC- β H1 cells by western blot (Fig. 1d) and by immunostaining in both EndoC- β H1 cells and primary human beta cells (Fig. 1e). Of note, there is no effect of time in culture (with or without cytokines) on *APOL* gene expression (ESM Fig 1a, b and d).

Finally, we assessed the contribution of individual cytokines on the induction of *APOL* genes in beta cells, and we found that *APOL* genes are mainly upregulated by IFN γ (ESM Fig. 1c).

Together, these data reveal that *APOL1*, *APOL2* and *APOL6* are specifically upregulated by inflammation in human beta cells.

Cytokine-induced *APOL* expression is mediated by the JAK–STAT pathway We next investigated which of the main inflammation-induced signalling pathways mediates the upregulation of *APOL* genes in human beta cells. NF- κ B pathway inhibition by salicylate or Bay 11-7082 did not affect cytokine-induced expression of *APOL1*, *APOL2* or *APOL6* (Fig. 2a), but blocked *TNFA* (also known as *TNF*) gene expression as expected (ESM Fig. 2a).

On the other hand, treatment with the JAK–STAT inhibitor baricitinib abolished cytokine-induced *APOL1/APOL2/APOL6* expression significantly both at 24 h and 72 h




Fig. 2 APOL expression is regulated by the JAK–STAT pathway. **(a, b)** EndoC-βH1 cells were exposed to IL-1β + IFNγ (Cytokines) for 72 h, alone or in combination with Bay 11-7082/salicylate (NF-κB inhibitors) **(a)** or 4 µmol/l baricitinib (JAK–STAT inhibitor) **(b)**. **(c, d)** EndoC-βH1 cells were transfected with siSTAT1 or non-targeting siRNA (Mock). After 48 h, the

cells were subjected to 24 h cytokine treatment (IL-1β + IFNγ). Gene expression of *STAT1* and *IRF1* **(c)** and *APOL1*, *APOL2* and *APOL6* **(d)** was analysed by qPCR and normalised to housekeeping genes *GAPDH* and *ACTB*. Results are the means ± SEM of 2–5 independent experiments; **p*<0.05; ***p*<0.01, ****p*<0.001, by unpaired Student’s *t* test





Fig. 3 *APOL* overexpression regulates beta cell death. EndoC- β H1 cells were transfected with control empty vector CMV-GFP (black bars) or overexpression constructs for *APOL1* (light blue) or *APOL2* (dark blue). (**a**, **d**) Gene expression was analysed by qPCR and normalised to housekeeping genes *GAPDH* and *ACTB*. (**b**, **c**) Cell death

was assessed by propidium iodide (PI; red)/Hoechst (blue) staining (**b**) and quantified with ImageJ (**c**). Scale bar, 500 μ m. Results are the means \pm SEM of 3–4 independent experiments; * p <0.05, ** p <0.01, *** p <0.001 by paired Student's *t* test compared with the CMV-GFP condition

(Fig. 2b), as well as the IFN γ -response genes *MX1*, *HLA-ABC* and *TNFA* as expected (ESM Fig. 2b).

In order to confirm the involvement of the JAK–STAT pathway, we specifically targeted *STAT1* using siRNA. *STAT1*

gene expression was very efficiently downregulated, resulting in reduced expression of its target gene *IRF1* (Fig. 2c). Furthermore, cytokine-induced upregulation of *APOL1* and 2 was strongly prevented upon downregulation of *STAT1* (Fig. 2d).



◀ **Fig. 4** *APOL1* knockdown reduces cytokine-induced cell death and expression of ER stress genes in EndoC- β H1. EndoC- β H1 cells were transfected with shCtrl (black bars) or shRNAs targeting *APOL1* (green), *APOL2* (dark purple) or *APOL6* (light purple) after 72 h of cytokine treatment (IL-1 β + IFN γ). Gene expression (**a**, **d**, **e**, **g**) was analysed by qPCR and normalised to housekeeping genes *GAPDH* and *ACTIN* ($n=4-5$). (**b**, **c**) Cell death was assessed by propidium iodide (PI; red)/Hoechst (blue) staining (**b**) and quantified with ImageJ (**c**). Scale bar, 500 μ m. (**f**) Protein levels of phospho-STAT1 (Tyr701) (p-STAT1), total STAT1 (STAT1) and GAPDH (as loading control) were analysed by western blotting and quantified. Results are the means \pm SEM of 3–5 independent experiments. * $p<0.05$, ** $p<0.01$, *** $p<0.001$, by paired Student's t test compared with the indicated condition

APOL gene overexpression upregulates ER stress To investigate the role of *APOL* genes in beta cells, we overexpressed *APOL1* and *APOL2* by lentiviral transduction in EndoC- β H1 cells (Fig. 3a). We observed a trend towards an increased cell death for both *APOL* genes even though the differences failed to reach statistical difference ($p=0.06$ [*APOL1*] and $p=0.08$ [*APOL2*]) (Fig. 3b,c).

In addition, *APOL1* upregulation led to a significant increase of the pro-apoptotic ER stress genes *ATF3* and *CHOP* at 48 h post-transduction (Fig. 3d). Along the same lines, we observed an increase in *ATF3* expression with *APOL1* and 2 overexpression in HEK293T cells (ESM Fig. 3a,b). No change in the protein levels of phosphorylated STAT1 was found upon *APOL1* or *APOL2* overexpression, which indicates overall no change in JAK–STAT pathway activation (ESM Fig. 3c, d). Of note, *ATF3* was also found to be upregulated upon cytokine treatment (ESM Fig. 4a,b,c).

APOL1 downregulation prevents cytokine-induced beta cell death and interferon-associated response Our data so far revealed that *APOL* genes are upregulated upon inflammation and that they could have a detrimental effect on human beta cells. We therefore investigated whether *APOL* gene downregulation could protect against cytokine-induced beta cell damage. We knocked down *APOL1*, *APOL2* or *APOL6* gene expression in cytokine-treated EndoC- β H1 cells leading to a >80% reduced expression of all three genes (Fig. 4a). Strikingly, we found that downregulation of *APOL1* abolished cytokine-induced beta cell death (Fig. 4b,c). This effect was associated with a reduced expression of the cytokine-induced pro-apoptotic ER stress markers *ATF3* and *CHOP* by 39% and 33% via *APOL1* knockdown (Fig. 4d).

Next, we checked the expression of mediators and target genes of the interferon response. We found that cytokine-induced *IRF1* and *STAT1* expression was significantly reduced by *APOL1* knockdown (34% and 50%, respectively) and *IRF1* by *APOL2* knockdown (48%) (Fig. 4e). *APOL6* knockdown did not decrease the expression of the aforementioned genes. In line with gene expression data, exposure to

IL-1 β + IFN γ increased phosphorylated STAT1, but this was not significantly decreased by *APOL1* and *APOL2* knockdown (Fig. 4f). Finally, *APOL1* downregulation prevented the increase in inflammation-induced expression of target genes *MX1* and *HLA-ABC* by 35% and 27%, respectively (Fig. 4g).

APOL genes are upregulated in human beta cells from donors with type 2 diabetes Finally, we asked whether these findings have any significance in pathophysiological conditions. We merged and analysed four publicly available single-cell transcriptomic datasets of primary human islet cells from donors with type 2 diabetes [33–36] (Fig. 5a, ESM Fig. 5a). *APOL2* and 6 genes were the most highly expressed in beta cells from donors without diabetes, while expression of *APOL1*, *APOL3* and *APOL4* in beta cells was very low and *APOL5* was undetectable (Fig. 5b; ESM Fig. 5b and data not shown).

Furthermore, we found that *APOL 2, 4* and 6 were significantly upregulated in beta cells from donors with type 2 diabetes compared with donors without diabetes (Fig. 5c; ESM Table 4). Interestingly, additional pathway analysis (ESM Fig. 5d,e) showed an enrichment of the interferon pathway in beta cells from the donors with type 2 diabetes analysed compared with donors without diabetes mellitus. Some over-represented genes found were *STAT2*, *IRF9* and *IFI6*, all interferon-regulated genes.

Next, we assessed *APOL1, 2* and 6 protein expression by western blot in isolated human islets obtained in our facility (Fig. 5d,e). We observed a significantly higher protein expression of *APOL1* by 12.8-fold in islets from three donors with (pre-)diabetes, while *APOL2* and *APOL6* were not significantly altered in these donors. The increase in *APOL1* was confirmed by immunostaining in a pancreas section of another donor with type 2 diabetes (Fig. 5f). *APOL2* and *APOL6* were also found to be upregulated in beta cells of this donor.


Of note, the upregulation of *APOL* genes was not restricted to beta cells as it was also seen in the single-cell RNA-seq data (see ESM Fig. 5c and ESM Table 5).

Overall, despite inter-donor differences, we found an upregulation of *APOL* genes in beta cells of donors with a history of type 2 diabetes.

Discussion

Here, we show that *APOL* genes are expressed in human pancreatic beta cells and expression of *APOL1, 2* and 6 is upregulated upon inflammatory conditions. Furthermore, we propose that *APOL* gene upregulation plays a role in the amplification of inflammation in beta cells.

APOL gene expression was significantly increased upon cytokine stress, particularly by IFN γ , but not upon other



◀ **Fig. 5** APOL family members are upregulated in islets from donors with type 2 diabetes. (a) Schematic representation of the transcriptomic analysis data used to study gene expression in beta cells from donors with type 2 diabetes (T2DM; $n=12$) in comparison with donors without diabetes (no diabetes [ND]; $n=24$); datasets from [33–36]. Created with BioRender.com. (b) Violin plots showing gene expression for different *APOL* genes in beta cells from donors without diabetes. (c) Volcano plot representing the differential expression of *APOL* genes in donors with type 2 diabetes. (d–f) APOL1, APOL2 and APOL6 protein expression determination by western blotting (d, e) in islets from donors without diabetes (ND; $n=3$) and with (pre) diabetes (preDM/T2DM; $n=3$). Fluorescence microscopy (f) of APOL1, APOL2 and APOL6 (green), C-peptide (red) and DAPI for nuclei (blue) in islets from donors with type 2 diabetes (T2DM) and without diabetes (ND). Scale bar, 50 μm . Results are the means \pm SEM of three independent experiments (d, e); * $p<0.05$, by unpaired Student's *t* test

ER stress conditions such as thapsigargin, high glucose or palmitate, which are associated with beta cell dysfunction and/or damage. The results from this study point towards a specific inflammatory regulation of this gene family, in agreement with observations in other cell types where *APOL* genes were also reported as interferon-response genes [15, 17, 26, 37–39].

Moreover, we uncovered that *APOL* genes are upregulated in beta cells from patients with type 2 diabetes mellitus, a condition associated with low-grade inflammation. This is in line with recent studies reporting an association between APOL1 levels in serum and increased risk of type 2 diabetes [27] and the metabolic syndrome [29]. Whether an increase in *APOL* genes can (negatively) influence insulin secretion and contribute to the inflammation-induced beta cell dysfunction that occurs in type 2 diabetes remains to be further investigated. In addition, this study was focused on the role of endogenous *APOL* genes in beta cells. Future studies assessing the impact of exogenous APOL1 on beta cells could contribute to the understanding of the role of elevated APOL1 levels in serum, which are associated with type 2 diabetes risk [27].

We found that *APOL1*, *APOL2* and *APOL6* expression in human beta cells is mediated by the inflammatory JAK–STAT pathway. Other studies have shown that Sp1, IRF1 and IRF2 can bind to the *APOL1* promoter in hepatoma cells [40], and IRF1, IRF2 and STAT2 to the *APOL1* promoter in podocytes and endothelial cells [17]. In addition, the authors of this latter study showed that NF- κ B inhibitors downregulate poly(I:C)-induced *APOL1* expression, although NF- κ B subunits did not bind to the *APOL1* promoter directly [17]. In our study, we did not observe a role for the NF- κ B pathway in regulating *APOL* gene expression. However, we found that downregulation of *APOL1* and *APOL2* in cytokine-treated beta cells was associated with a decrease in IRF1 and STAT1 both at gene and protein levels.

Importantly, ER stress is one of the factors that contributes to the loss of beta cell function in both type 1 diabetes [41] and type 2 diabetes [42], as well as promoting beta cell death [43]. In this study, we showed that *APOL1* or *APOL2* overexpression led to a modest increase in the pro-apoptotic ER stress genes *ATF3* and *CHOP* in EndoC- β H1 cells, and a much stronger induction in HEK293T cells. By contrast, downregulation of *APOL1* gene expression prevented cytokine-induced apoptosis, paralleled by a decrease in ER stress and inflammatory gene expression. A direct contribution of wild type *APOL* genes on induction of ER stress in beta cells will require more evidence, especially in other models, including primary human beta cells. Previous studies have reported that *APOL1* risk variants can induce ER stress in human podocytes [44] and podocyte-like cells from *Drosophila* [45]. Interestingly, inhibition of ER stress likewise prevented APOL1-mediated cell death [44, 45]. *APOL* gene overexpression, especially *APOL1* and *APOL6*, has been reported to promote apoptosis in embryonic kidney cells [46], podocytes [47] and colorectal cancer cell lines [24].

APOL2 downregulation resulted in a decrease in ER stress and inflammation, while no change was detected in beta cell death. APOL2 has been reported to have an anti-apoptotic role in human bronchial epithelial cells [14] and HeLa cells [15]. Our results also contrast with the work from Liao et al, which showed that *APOL2* knockdown sensitised cells to IFN γ cytotoxicity [14], while Galindo-Moreno et al found no effect of *APOL2* knockdown in IFN γ -induced cell death [15]. Thus the function of *APOL* genes may be partly cell-type specific.

The results from this study indicate that APOL1, APOL2 and APOL6 are overall detrimental. While the role of APOL1 appears to be pro-apoptotic in this and previous work, more studies are needed to decipher the role of other APOLs such as APOL2 and APOL6. Of note, we observed that the *APOL2* expression levels of untreated control beta cells were higher in comparison with other *APOL* genes. Thus, the presence of *APOL2* might be important in maintaining beta cell health up to a certain threshold, after which it could become toxic and eventually trigger cell death. Regarding *APOL6*, earlier studies showed that knockdown inhibited IFN γ -induced apoptosis in atherosclerotic muscle cells [26], implying a negative role for this gene. Yet, we only found a moderate decrease on the levels of ER stress and inflammatory genes upon downregulation of *APOL6* in beta cells exposed to cytokines.

Overall, this study uncovers APOLs as a new gene family that has an implication in beta cell inflammation, and therefore potentially in the onset and/or progression of diabetes mellitus. In conclusion, APOLs appear to be relevant in beta cell health and stress and may be promising targets for reducing progressive beta cell failure.

Supplementary Information The online version of this article (<https://doi.org/10.1007/s00125-023-06033-z>) contains peer-reviewed but unedited supplementary material.

Acknowledgements The authors thank R. C. Hoeben and M. Rabelink from the viral vector facility (Dept of Cell & Chemical Biology, Leiden University Medical Center) for the production of lentiviral vectors. We also thank S. du Pré (Dept of Internal Medicine, Leiden University Medical Center) for careful reading of the manuscript.

Data availability scRNAseq data generated by our laboratory and used in this study are available in the Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/), accession number GSE218316.

Funding FC and EJPdK have received funding from the DON Foundation, the Dutch Diabetes Research Foundation, JDRF, the Bontius Foundation and the Novo Nordisk Foundation Center for Stem Cell Medicine reNEW (NNF21CC0073729).

Authors' relationships and activities The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement MP-B and FC designed experiments and wrote and revised the manuscript. FC and EJPdK received the funding and contributed to the interpretation of the results. MP-B performed experiments and the analysis and interpretation of the results. AMG and TJJdW performed the RNA-sequencing analysis. NdG, MvA, LD, EvdS, FL and AvdS contributed to performing experiments. AZ contributed to the cloning and generation of lentiviral vectors and to the data interpretation. All authors reviewed the article and approved the final version of the manuscript. FC is the guarantor of this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Grunnet LG, Aikin R, Tonnesen MF et al (2009) Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. *Diabetes* 58(8):1807–1815. <https://doi.org/10.2337/db08-0178>
- Burke SJ, Stadler K, Lu D et al (2015) IL-1beta reciprocally regulates chemokine and insulin secretion in pancreatic beta-cells via NF-kappaB. *Am J Physiol Endocrinol Metab* 309(8):E715–726. <https://doi.org/10.1152/ajpendo.00153.2015>
- Dettmer R, Niwolik I, Cirksena K et al (2022) Proinflammatory cytokines induce rapid, NO-independent apoptosis, expression of chemotactic mediators and interleukin-32 secretion in human pluripotent stem cell-derived beta cells. *Diabetologia* 65(5):829–843. <https://doi.org/10.1007/s00125-022-05654-0>
- Pedersen SS, Prause M, Williams K, Barres R, Billestrup N (2022) Butyrate inhibits IL-1beta-induced inflammatory gene expression by suppression of NF-kappaB activity in pancreatic beta cells. *J Biol Chem* 298(9):102312. <https://doi.org/10.1016/j.jbc.2022.102312>
- Moore F, Naamane N, Colli ML et al (2011) STAT1 is a master regulator of pancreatic beta-cell apoptosis and islet inflammation. *J Biol Chem* 286(2):929–941. <https://doi.org/10.1074/jbc.M110.162131>
- Nardelli TR, Vanzela EC, Benedicto KC et al (2018) Prolactin protects against cytokine-induced beta-cell death by NFkappaB and JNK inhibition. *J Mol Endocrinol* 61(1):25–36. <https://doi.org/10.1530/JME-16-0257>
- Brozzi F, Nardelli TR, Lopes M et al (2015) Cytokines induce endoplasmic reticulum stress in human, rat and mouse beta cells via different mechanisms. *Diabetologia* 58(10):2307–2316. <https://doi.org/10.1007/s00125-015-3669-6>
- Cardozo AK, Ortis F, Storling J et al (2005) Cytokines down-regulate the sarcoendoplasmic reticulum pump Ca²⁺ ATPase 2b and deplete endoplasmic reticulum Ca²⁺, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. *Diabetes* 54(2):452–461. <https://doi.org/10.2337/diabetes.54.2.452>
- Rosenzweig M, Salet R, Lorenzon R et al (2020) Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I/II randomised, double-blind, placebo-controlled, dose-finding study. *Diabetologia* 63(9):1808–1821. <https://doi.org/10.1007/s00125-020-05200-w>
- von Herrath M, Bain SC, Bode B et al (2021) Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Diabetes Endocrinol* 9(4):212–224. [https://doi.org/10.1016/S2213-8587\(21\)00019-X](https://doi.org/10.1016/S2213-8587(21)00019-X)
- Ehse JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. *Proc Natl Acad Sci U S A* 106(33):13998–14003. <https://doi.org/10.1073/pnas.0810087106>
- Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K (2008) The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. *Endocrinology* 149(5):2208–2218. <https://doi.org/10.1210/en.2007-1059>
- Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N Engl J Med* 356(15):1517–1526. <https://doi.org/10.1056/NEJMoa065213>
- Liao W, Goh FY, Betts RJ et al (2011) A novel anti-apoptotic role for apolipoprotein L2 in IFN-gamma-induced cytotoxicity in human bronchial epithelial cells. *J Cell Physiol* 226(2):397–406. <https://doi.org/10.1002/jcp.22345>
- Galindo-Moreno J, Iurlaro R, El Mjiyad N, Diez-Perez J, Gabaldon T, Munoz-Pinedo C (2014) Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein. *Cell Death Dis* 5(6):e1275. <https://doi.org/10.1038/cddis.2014.237>
- Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA (2008) ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. *Autophagy* 4(8):1079–1082. <https://doi.org/10.4161/auto.7066>
- Nichols B, Jog P, Lee JH et al (2015) Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. *Kidney Int* 87(2):332–342. <https://doi.org/10.1038/ki.2014.270>
- Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F et al (2005) Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. *Science* 309(5733):469–472. <https://doi.org/10.1126/science.1114566>

19. Thomson R, Genovese G, Canon C et al (2014) Evolution of the primate trypanolytic factor APOL1. *Proc Natl Acad Sci U S A* 111(20):E2130–2139. <https://doi.org/10.1073/pnas.1400699111>
20. Page NM, Butlin DJ, Lomthaisong K, Lowry PJ (2001) The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. *Genomics* 74(1):71–78. <https://doi.org/10.1006/geno.2001.6534>
21. Albert TS, Duchateau PN, Deeb SS et al (2005) Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL. *J Lipid Res* 46(3):469–474. <https://doi.org/10.1194/jlr.M400304-JLR200>
22. Valsecchi M, Cazzetta V, Oriolo F et al (2020) APOL1 polymorphism modulates sphingolipid profile of human podocytes. *Glycoconj J* 37(6):729–744. <https://doi.org/10.1007/s10719-020-09944-w>
23. Vanwalleghem G, Fontaine F, Lecordier L et al (2015) Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1. *Nat Commun* 6:8078. <https://doi.org/10.1038/ncomms9078>
24. Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA (2005) Apolipoprotein L6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. *Mol Cancer Res* 3(1):21–31. <https://doi.org/10.1158/1541-7786.21.3.1>
25. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA (2008) Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. *J Biol Chem* 283(31):21540–21549. <https://doi.org/10.1074/jbc.M800214200>
26. Zhaorigetu S, Yang Z, Toma I, McCaffrey TA, Hu CA (2011) Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells. *J Biol Chem* 286(31):27389–27398. <https://doi.org/10.1074/jbc.M110.210245>
27. Croyal M, Wargny M, Chemello K et al (2022) Plasma apolipoprotein concentrations and incident diabetes in subjects with pre-diabetes. *Cardiovasc Diabetol* 21(1):21. <https://doi.org/10.1186/s12933-022-01452-5>
28. Duchateau PN, Movsesyan I, Yamashita S et al (2000) Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. *J Lipid Res* 41(8):1231–1236. [https://doi.org/10.1016/S0022-2275\(20\)33430-1](https://doi.org/10.1016/S0022-2275(20)33430-1)
29. Nishimura K, Murakami T, Sakurai T et al (2019) Circulating apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism. *Sci Rep* 9(1):14869. <https://doi.org/10.1038/s41598-019-51367-7>
30. Duchateau PN, Pullinger CR, Orellana RE et al (1997) Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. *J Biol Chem* 272(41):25576–25582. <https://doi.org/10.1074/jbc.272.41.25576>
31. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. *Diabetes Care* 33(Suppl 1):S62–69. <https://doi.org/10.2337/dc10-S062>
32. Ravassard P, Hazhouz Y, Pechberty S et al (2011) A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. *J Clin Invest* 121(9):3589–3597. <https://doi.org/10.1172/JCI58447>
33. Wang YJ, Schug J, Won KJ et al (2016) Single-cell transcriptomics of the human endocrine pancreas. *Diabetes* 65(10):3028–3038. <https://doi.org/10.2337/db16-0405>
34. Xin Y, Kim J, Okamoto H et al (2016) RNA sequencing of single human islet cells reveals type 2 diabetes genes. *Cell Metab* 24(4):608–615. <https://doi.org/10.1016/j.cmet.2016.08.018>
35. Enge M, Arda HE, Mignardi M et al (2017) Single-cell analysis of human pancreas reveals transcriptional signatures of aging and somatic mutation patterns. *Cell* 171(2):321–330 e314. <https://doi.org/10.1016/j.cell.2017.09.004>
36. Segerstolpe A, Palasantza A, Eliasson P et al (2016) Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. *Cell Metab* 24(4):593–607. <https://doi.org/10.1016/j.cmet.2016.08.020>
37. Carlotti F, Bazuine M, Kekarainen T et al (2004) Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. *Mol Ther* 9(2):209–217. <https://doi.org/10.1016/j.ymthe.2003.11.021>
38. Kreit M, Vertommen D, Gillet L, Michiels T (2015) The interferon-inducible mouse Apolipoprotein L9 and prohibitins cooperate to restrict Theiler's virus replication. *PLoS One* 10(7):e0133190. <https://doi.org/10.1371/journal.pone.0133190>
39. Gaudet RG, Zhu S, Halder A et al (2021) A human apolipoprotein L with detergent-like activity kills intracellular pathogens. *Science* 373(6552):eabf8113. <https://doi.org/10.1126/science.abf8113>
40. Wang DP, Yu ZX, He ZC et al (2020) Apolipoprotein L1 is transcriptionally regulated by SP1, IRF1 and IRF2 in hepatoma cells. *FEBS Lett* 594(19):3108–3121. <https://doi.org/10.1002/1873-3468.13887>
41. Tersey SA, Nishiki Y, Templin AT et al (2012) Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. *Diabetes* 61(4):818–827. <https://doi.org/10.2337/db11-1293>
42. Brusco N, Sebastiani G, Di Giuseppe G et al (2023) Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes. *Diabetologia* 66(2):354–366. <https://doi.org/10.1007/s00125-022-05814-2>
43. Laybutt DR, Preston AM, Akerfeldt MC et al (2007) Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. *Diabetologia* 50(4):752–763. <https://doi.org/10.1007/s00125-006-0590-z>
44. Wen H, Kumar V, Lan X et al (2018) APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress. *Biosci Rep* 38(4):BSR20171713. <https://doi.org/10.1042/BSR20171713>
45. Gerstner L, Chen M, Kampf LL et al (2022) Inhibition of endoplasmic reticulum stress signaling rescues cytotoxicity of human apolipoprotein-L1 risk variants in *Drosophila*. *Kidney Int* 101(6):1216–1231. <https://doi.org/10.1016/j.kint.2021.12.031>
46. Olabisi OA, Zhang JY, VerPlank L et al (2016) APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. *Proc Natl Acad Sci U S A* 113(4):830–837. <https://doi.org/10.1073/pnas.1522913113>
47. Lan X, Jhaveri A, Cheng K et al (2014) APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. *Am J Physiol Renal Physiol* 307(3):F326–336. <https://doi.org/10.1152/ajprenal.00647.2013>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.